Detalhe da pesquisa
1.
High CD34-positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft-versus-host disease or mortality.
Transfusion
; 64(6): 1068-1075, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38693089
2.
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Lancet Oncol
; 22(10): 1391-1402, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534514
3.
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
Blood
; 134(7): 606-613, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31186274
4.
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.
Blood
; 128(2): 195-203, 2016 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27247136
5.
Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.
Curr Oncol Rep
; 19(9): 61, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28755313
6.
Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant.
Acta Haematol
; 133(4): 347-53, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25677780
7.
Abnormalities in IgA and IgM are associated with treatment-resistant ITP.
Blood
; 119(21): 5016-20, 2012 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-22490683
8.
Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma.
Adv Ther
; 39(6): 2630-2640, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35397110
9.
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Lancet Haematol
; 9(5): e327-e339, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35366963
10.
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
Blood Adv
; 3(7): 1167-1174, 2019 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30967392
11.
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Lancet Haematol
; 6(1): e38-e47, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30558987
12.
The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia.
Curr Opin Oncol
; 20(6): 690-6, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18841052
13.
Targeted therapy for chronic lymphocytic leukemia: current status and future directions.
Drugs
; 75(2): 143-55, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25619739
14.
B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292.
Immunotargets Ther
; 3: 29-38, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-27471698
15.
Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use.
Ther Adv Hematol
; 3(6): 375-89, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23606939
16.
Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia. [corrected].
Hematology Am Soc Hematol Educ Program
; 2011: 119-20, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22160022